P ersistent infection with hepatitis C virus (HCV) is the predominant cause of chronic liver disease in the United States, and the World Health Organization recently estimated that 3% of the world's population has been infected with this pathogen. 1 This statistic suggests those 170 million chronic carriers of HCV are at risk for developing cirrhosis and/or liver cancer. Together with alcoholic liver disease, hepatitis C is the most common cause of cirrhosis and the major indication for liver transplantation in the United States. After liver transplantation, recurrence of HCV infection is common, but in many cases, the hepatitis is mild and the long-term survival rate averages 65% after 5 years. 2 At the current rate of infection, the pool of patients with chronic hepatitis C would increase by 4% in the next decade. At the current attack rate of infection, the number of deaths caused by HCV in the United States is estimated at 8,800/yr, but by the year 2008, this may reach 35,000. 3 Despite increasing experience in the medical and surgical management of HCV-related disease, this pathogen, its biological characteristics, and the tempo of recurrence using a varying immunosuppressive cocktail are not completely understood. These notions compel liver transplantation physicians to rapidly familiarize themselves with HCV. Toward this end, this review integrates current knowledge of the molecular mechanisms of HCV pathogenesis.
Toward the end of the 1980s, a significant number of cases of parenterally transmitted viral hepatitis could not be ascribed to any of the hepatic viruses known at that time (hepatitis A, hepatitis B, and hepatitis delta viruses). The discovery and characterization of a novel RNA virus with characteristics typical of the family Flaviviridae 4 provided the tools to study the epidemiological importance of this agent in these cases of Non A Non B hepatitis (NANBH). The virus, known as HCV, was shown to be the cause of most cases of NANBH. More than 50% of the patients become chronic carriers. 5 The persistent infection commonly results in chronic active hepatitis, which may lead to liver cirrhosis and hepatocellular carcinoma. 6, 7 Random screening of blood donor populations has indicated as many as 500 million chronic carriers of the virus worldwide, highlighting HCV as a major human pathogen. 8 
Biological Process of Infection
To discuss the relevance of antiviral therapy and its future, it is necessary to first review current knowledge of the virus. Unfortunately, approaches to the development of in vitro replication systems for propagation of this virus have been particularly difficult, and reliable systems for efficient long-term virus replication are irreproducible. Nevertheless, reports of virus replication have been made using systems from hepatic tissue 9 and peripheral-blood mononuclear cells. 10 In vitro infection systems have been reported from human Tand B-cell lines, 11, 12 human fetal liver cells, 13 and chimpanzee hepatocytes. 14 One of the most promising in vitro infection systems reported to date uses human hepatoma cells in which a subgenomic portion of the virus persisted for up to a year postinfection. 104 Additional evidence was reported by Sun and Feitelson 15 that HepG2 cells are tropic and supportive of a consensus HCV RNA genome. Data reported by Mizutani et al 16 and Sugiyama et al 17 using the human T-lymphotrophic virus type 1-infected T-cell (HTLV-1) line, MT-2, also supported viral expression. In these studies, there was apparent selection from the viral quasispecies of a single genomic sequence, presumably representing a virus naturally adapted for growth in this cell line. Whether the viruses in these studies, which are apparently adapted for tissue culture growth, can replicate in other cell lines remains to be established.
Animal models of HCV infection have been as challenging to devise as the dissection of the virus itself. The chimpanzee was recognized early as a useful study subject in the pathogenesis of HCV. Early in the field of HCV research, the chimpanzee model proved critical to the determination of the physicochemical analysis of the virus. For instance, treatment of infectious human sera with lipid solvents led to viral inactivation, thus identifying its harbored lipid envelope. 18 The model was also used for evaluating a number of procedures for inactivating the virus in biological products, such as formalin, chloroform, heat, and ultraviolet radiation.
The greatest benefit from the chimpanzee model was making genetic characterization of the virus possible. In this model, the nonhuman primate was used as an in vivo propagation system to achieve sufficient quantities of virus to perform sequencing and mutational analysis.
Despite its cost and obvious limitations, information from nonhuman primates has led to a plethora of critical molecular observations. A brief list of these achievements follows: (1) genetic drift occurs in the hypervariable region (HVR) of the envelope proteins, (2) antibodies directed against these epitopes may be protective in naive subjects, (3) regions of the viral genome critical to in vitro infection are also essential in live subjects, and (4) the nature and tempo of the early cellular immune response dictates viral eradication versus chronic infection. A recent presentation by Barry et al 19 from Stanford University on the use of complementary DNA microarray (gene chip) technology showed a pattern of genetic responses within the livers of chimpanzees inoculated with HCV. In this provocative report, the evaluation of hepatic messenger RNA after HCV infection (24 hours) showed a classic inflammatory response, angiogenesis, and attenuation of extracellular matrix degradation. Later time points (3 days) confirmed a T-lymphocyte presence but an attenuated CD4 response.
Two other novel systems are worth mentioning, although their contributions remain to be seen. Xie et al reported on the successful infectivity of primary hepatocytes obtained from the tree shrew, Tupaia belangeri, a small primate, using HCV-positive serum. The study only examined short-term parameters, but the prospect of a small-animal model for such studies is hopeful. 20 A unique murine system, referred to as the Trimera Mouse System, has been devised at the Weizmann Institute of Science for the in vivo analysis of human viruses. 21 In this experimental model, normal mice are prepared for implantation of normal or virally infected liver by lethal irradiation, followed by severe combined immunodeficiency mouse bone marrow reconstitution. The durability of this system to show HCV in the serum extended to greater than 30 days. 105 The system is currently being used for the evaluation of antiviral compounds and neutralizing antibody preparations. Examination of the viral particle itself has shed light on a potential mechanism for viral entry into human tissue. The size of the viral particle (virion) was previously estimated at 80 nm by ultracentrifugation, 22 whereas filtration studies suggested 30 Ϯ 60 nm. 23 Several studies have shown that the buoyant density of HCV in infectious serum is less than that in noninfectious serum, 24 and the density (1 Ϯ 06 g/mL) suggested an association with the low-density lipoprotein (LDL) fraction, 25 which was subsequently verified by Prince et al. 26 Typically, HCV-infected serum also contains a higher density fraction in which the virus isadherent to immunoglobulins. 24 As expected, virus in the lipoprotein fraction appears to be relatively more infectious than the antibody-coated fraction. Using very low-density lipoprotein (VLDL)-associated virus, highly purified particles have been observed that appear to have prominent spikes on their surface, 27 probably representing glycoprotein portions of the viral lipid coat. The observation of an association between HCV and lipoproteins may be critical for the virus replication cycle because LDL and VLDL are taken up by hepatocytes through the LDL receptor (LDLR, discussed next).
Identifying the HCV Receptor
Insight into the mechanism by which HCV gains entry into host cells is critical to understanding primary infection and reinfection posttransplantation. Current research has focused on 2 molecular ligands as loci for viral attachment and entry into human tissue (Fig. 1) . As previously mentioned, an early observation in the study of HCV is its association with the lipoprotein fraction of human sera. The observation that HCV is associated with LDL, 26 VLDL, 26, 28 and immunoglobulins 24, 25, 29 has led to the assumption that these complexes favor binding of the virus to target cells. LDL is internalized by LDLR-mediated endocytosis. 30 The LDLR is the main representative of a family of cell-surface receptors (LDLR gene family) that share characteristic sequences; for example, a ligand-binding domain. 31 Members of the LDLR gene family function as receptors for minor-group common cold virus 32 and subgroup A Rous sarcoma virus. 33 This suggests the Kenneth E. Drazan possibility that the LDLR (or members of the gene family) might also function as a receptor for HCV. Although these studies provide firm evidence for HCV virion binding to the LDLR, internalization through this ligand was not shown.
More convincing evidence was presented in a recent study in which cells and mice null for LDLR that were resistant to viral entry were rendered susceptible to infection by genetic engineering with the human LDLR. 34 At present, it must be considered that other receptors for HCV belonging to the LDLR gene family or others exist that may also mediate the binding and uptake of HCV.
A second suspect responsible for HCV tropism is CD81. 35 The HCV envelope protein, E2, binds human CD81, 36 a ubiquitously expressed transmembrane molecule belonging to the family of tetraspanins. CD81 expression on B lymphocytes has been shown to be critical for HCV envelope protein E2 binding. 37 Does this prove that CD81 is the cellular receptor for HCV? Certainly not, but the findings of CD81 localizing with HCV has interesting implications for the coexistent syndromes manifest in patients with chronic active hepatitis C. HCV infection is associated with B-cell lymphoproliferative disorders, such as mixed-type II cryoglobulinemia 38 and non-Hodgkin's lymphoma. 39 On B cells, it has been observed that CD81 is a member of a signaling complex which regulates the threshold for B-cell activation and proliferation. Could a population of individuals exist with CD81 polypmorphisms such that they may be resistant to HCV tropism? Unfortunately, no clinical studies to date have identified such individuals. Although murine models of CD81 knockouts have been developed without lethality, 40 testing HCV infection in this experimental model is untenable because of lack of species tropism.
Molecular Analysis of the HCV Genome
The genomic organization of HCV is shown schematically in Figure 2 . Genomic organization of HCV RNA indicated the virus is closely related to the pestivirus genera within the family, Flaviviridae, but has now been classified in its own subgenera, Hepacicvirus. The viral genome is a single-stranded RNA molecule approximately 9.5 kb in length that is positive sense and possesses a unique open-reading frame, coding for a single polyprotein. The viral genome is flanked by untranslated regions (UTRs) at its 5Ј and 3Ј ends. The length of the polyprotein-encoding region varies according to the isolate and genotype of the virus from 3,008 to 3,037 amino acids. 41 Apart from differences in length, HCV genotypes (subfamilies) show diversities of approximately 30% in the nucleotide sequences of their whole, showing at least 6 genotypes and more than 30 subtypes throughout the world. 42 The importance of the genomic heterogeneity is that some genotypes appear to be associated with more severe pathological states and are more refractory to treatment. 42 Genotyping is becoming a common clinical assay in the management of newly diagnosed HCV, but not during clinical flare or after liver transplantation.
5ЈUTR
An obvious characteristic of HCV is the presence of a long UTR at the 5Ј end of the genome, and detailed molecular analysis indicates polyprotein synthesis is initiated at the internal end of this region. 43 This region of the genome was predicted by its primary sequence to form extensive secondary structures, 44 ; Figure 1 . HCV particles are associated with LDL and VLDL molecules in the circulation of infected humans. In addition, the LDL receptor has been identified as capable of transporting HCV particles across the cell membrane. CD81 is a ubiquitously expressed tetraspan molecule that also associates with HCV. The viral envelope protein, E2, binds 1 of the extracellular domains of CD81; however, the consequence of this discrete interaction is less well understood. After viral binding to its cellular receptor, HCV sheds its lipid envelope to deliver its genetic load (RNA) and structural proteins into the cytosol. 
Molecular Biology of HCV
which were biochemically confirmed by Brown et al. 45 Furthermore, a survey of the sequences within the 5Ј UTR from 39 different isolates and genotypes of HCV showed remarkable sequence conservation. 46 This region is the most conserved of the genome, a characteristic allowing it to be used as a diagnostic locus (genotype) and marker (HCV RNA) by polymerase chain reaction. 47 Within this region, the majority of genotypes of HCV possess a translation initiation locus closely resembling that of other RNA viruses, such as polio and influenza. 48 This genetic organization is termed an internal ribosomal entry site (IRES), which differentiates the mechanism for viral gene expression (cap independent) from nearly 98% of human gene products (cap dependent). 49 The function of the HCV IRES therefore seems to be to provide a structure able to specifically engage the ribosome for translation initiation (protein production; Fig. 3 ). As in other IRES examples (poliovirus, influenza virus, hepatitis A), this interaction probably involves complexes with cellular proteins. 50
Virus-Encoded Proteins
The nascent viral polyprotein is processed (matured and cleaved) by a combination of host and viral proteinases into mature structural proteins and nonstructural (NS) viral enzymes 51 (Fig. 3) . Proteolytic processing of the HCV polyprotein results in at least 10 distinct viral proteins: core (capsid), E1 (envelope), E2, NS2, NS3, NS4a, NS4b, NS5a, and NS5b. The structural proteins are located in the amino terminal (proximal) one third, and the replicative enzymes are located within the carboxy terminal (distal) two thirds of the polyprotein. The initial cleavage of the polyprotein is likely mediated by a host (human) signal proteinase. 52 The viral proteins themselves mediate further division of the polyprotein. 53 
Core
The protein located at the amino terminus of the polyprotein is highly basic in nature and considered likely to be the viral core (capsid) protein. It is released from the viral polyprotein by nascent proteolytic cleavage at amino acid 191 by cellular, not viral, proteases. 52 The subcellular trafficking of the core protein has been an area of interest. In particular, the nucleolar localization of core may be caused by its ability to bind to ribosomes assembled in the nucleus. 54 The biological functions of the core protein found in the nucleus, if this also occurs in natural virus replication, are still unclear. Several studies have reported the suppression by core of transcription of several host immunoregulatory genes, 55 as well as interference in expression of coinfecting genomes of hepatitis B 56 and human immunodeficiency viruses. 57 Perhaps the most interesting recent observations have been that core can specifically suppress apoptotic cell death in artificial systems 58 and also specifically interact with the cytoplasmic tail of the lymphotoxin-␤ receptor, a member of the tumor necrosis factor family. 59 Because lymphotoxin-␤ receptor is known to be involved in apoptotic signaling, this strongly suggests that core may have an immunomodulatory function and a critical role in the establishment of persistence and disease pathogenesis.
Finally, a recent report 60 shows an association between the core protein and the surface of lipid droplets within the cytoplasm. Analysis of the triglyceride populations within the cell indicates that core protein expression stimulates a change in cellular metabolism of triglycerides. Because a characteristic of HCV infection is liver steatosis, it is plausible that this is a result of the direct effect of the core protein on lipid metabolism.
Envelope Proteins E1 and E2
The major viral structural envelope proteins are the glycoproteins, E1 and E2, which are released from the viral polyprotein by the action of host-cell signal peptidases. Apart from the interest in understanding the biological processes of assembly and morphogenesis, both E1 and E2 have been extensively studied in terms of antigenic variation and mechanisms of persistence and are obviously major components of prototype vaccine studies for HCV. E2 presumably represents the most variable region of the HCV genome. 61 This variation is assumed to be caused by random mutation and selection of mutants capable of escaping from neutralizing antibodies produced in the host. Furthermore, antibodies against E2 correlate with protection from HCV challenge in chimpanzees. Direct assays are now available for neutralizing antibodies in serum 62 or in vitro culture. 29 Within the E2 sequence are regions of extreme hypervariability (HVR) that have been the focus of more detailed study; one specific domain is known as HVR-1. 63 This region has been suggested to be particularly important in HCV neutralization because of its extreme variability and because this variability was not observed in a patient with agammaglobulinemia, even over 2 to 5 years. 64 Antibodies to HVR-1 in patient sera have been shown to neutralize binding of E2, 65 whereas peptide antibodies raised to this region are able to block infection in tissue culture 66 and have shown efficacy in chimpanzee challenge experiments. 67 Despite this observed protective capacity of antibody, the extreme heterogeneity in the sequence of this epitope in diverse virus strains means that its use in a prophylactic vaccine strategy remains doubtful.
The most striking recent observation for E2 is its putative role in obstructing the innate immune response to HCV replication. 68 The HCV envelope protein, E2, contains a sequence identical with phosphorylation sites of the interferon (IFN)-inducible protein kinase (PKR), and the translation initiation factor, eIF2, a target of PKR. In this study, cells engineered to express E2 did not manifest normal kinase activity of PKR, resulting in unregulated protein synthesis and cell growth. This interaction of E2 and PKR may be one mechanism by which HCV circumvents the antiviral effect of interferon.
NS2
The NS2 protein is a transmembrane protein with its carboxy terminus translocated into the lumen of the endoplasmic reticulum (ER) while its amino terminus lies in the cytosol. 69 Although immunoprecipitation studies 51 showed that NS2 is closely associated with the structural proteins, the biological function of the majority of the NS2 protein is still unclear.
NS3
The region coding for the NS3 protein has been the most extensively studied of the entire genome. The NS3 protein has been shown in numerous studies to be approximately 70 kd and to possess several diverse biochemical functions. 70 Initial genomic analysis of this region of the molecule showed that it could be characterized as a serine protease. Studies subsequently showed that the NS3 protease was entirely responsible for proteolytic processing of the entire downstream region of the viral polyprotein. 71 The overall proteolytic pathway for the whole viral genome is shown in Figure 3 , implying that the NS3 protease mediates proteolysis at the NS3/NS4a, NS4a/NS4b, NS4b/ NS5a, and NS5a/NS5b junctions to release the mature NS3, NS4a, NS4b, NS5a, and NS5b proteins. However, there are subtle biochemical differences in the exact mechanism by which NS3 mediates these cleavages. Further analysis of the NS3 protein also showed motifs characteristic of RNA helicase enzymatic function (unwinding of RNA for replication and protein translation; Fig. 4) . 72 This molecule is therefore involved in critical events of viral replication, thus making it an attractive target for antiviral therapy.
NS4
The NS4 region of the polyprotein comprises 2 proteins; namely, NS4a and NS4b. Both these proteins are released from the viral polyprotein by the NS3 serine protease by cis cleavage at the NS3/NS4a and trans cleavage at the NS4a/NS4b and NS4b/NS5a junction. 73 NS4a is a small protein, approximately 8 kd, and appears to have diverse functions, such as anchorage of replication complexes and a cofactor for the NS3 protease (discussed previously). 74 Currently, there is no ascribed function for the NS4b protein, but it likely has an integral role within HCV replication complexes.
NS5a and NS5b
The NS5 region of the polyprotein is composed of 2 major proteins, NS5a and NS5b, which are released as mature products by the action of the NS3 protease in conjunction with NS4a. The functional role of NS5a is currently unclear. Apart from the probable role of NS5a in the HCV replication cycle, recent evidence suggested that it may be a critical factor in determining the susceptibility of the virus to treatment with IFN. It was initially reported that interferon sensitivity correlated with mutations within a discrete region of NS5a. Subsequently, this domain was named the IFN sensitivity-determining region. 75, 76 Further evidence indicated that this likely occurred through a direct interaction of NS5a with the IFN-induced protein kinase, PKR, a cellular mediator of IFN-induced antiviral resistance. 77, 78 Because PKR is a critical factor in the host response to IFN, 79 its inactivation by NS5a may be a major mechanism by which HCV evades the host immune response. 80 Furthermore, restrained PKR activity in the face of carcinogenic stress on cells infected with HCV (e.g., hepatocytes and B lymphocytes) may permit transformation into the malignant state. 81, 82 The sequence of the NS5b protein is highly conserved, not only between different strains of HCV, but also in other RNA viruses. In particular, the amino acid motif, G-D-D, is totally conserved in HCV, aviviruses, poliovirus, and tobacco mosaic virus. 83 This motif is a characteristic of all known RNA-dependent RNA polymerases (RdRp), and therefore the function of NS5b in HCV has been speculated to be the viral polymerase. The role of the viral polymerase in HCV replication is to convert the single-strand genome into a faithful intermediate negative strand for subsequent and repetitive production of positive strands for virion production (Fig. 4) . 74 This step in the viral replication cycle is responsible for the creation of quasispecies (unfaithfully reproduced genomes). 84 This inefficient editing process, also present in HIV infection, 85 may represent a ''trojan horse'' viral evasion strategy of creating decoy virions or genomes for host cell defense.
3ЈUTR
A significant recent finding in the HCV area was that the considered 3Ј terminal region of the genome was incorrect. A number of studies suggested that the 3Ј terminus of the genome terminated in a poly (U) tract 106 or, in another report, 44 as a poly (A) tract. However, more detailed analysis of the 5Ј end of the negative antigenomic RNA strand in infected liver cells showed the presence of a novel 98-nucleotide sequence downstream of the presumed genomic terminus. 86, 87 Detailed sequence analysis of the complete new 3ЈUTR shows that it can be considered a tripartite structure comprising the conventional 3Ј end, a poly (U) tract, and the new highly conserved sequence known as the 3ЈX tail. 88 Interestingly, the poly (U) region appears to be extremely heterogeneous between different virus isolates and even within the same infected liver. In contrast, the new sequence is highly conserved even between the 2 most genetically divergent HCV genotypes, 1B and 2A. 88 The 3ЈUTR, like its 5Ј counterpart, is highly associated with cellular host proteins, likely part of the virion assembly and replicase complex.
Emerging Strategies for Therapy
Current approaches to the treatment of NANBH are limited to the use of IFN-␣, either alone 89 or in combination with other agents, such as ribavirin. 90 The efficacy of these therapies is extremely poor, and the posttherapy relapse rate is very high, such that sustained biochemical response is observed in less than 20% of the patients. 91 Consequently, there is an urgent need for the development of novel therapeutics. The antiviral effect of IFN results from both inhibition of viral replication 92, 93 and modulation of the immune response to viral epitopes. As recently suggested by mathematical models, the major initial effect of IFN-␣ is to block virion production or release, 94 but the subsequent second-phase decline is believed to reflect the death rate of productively infected cells, in which HCV-specific cytotoxic T-cell activity could be a major contributor. The mechanism of synergism provided by ribavirin is also unknown, but its benefit has been clearly achieved. 95 The 5Ј-triphosphate metabolite of ribavirin is believed to act as an inhibitor of the viral RdRp. However, two other non-mutually exclusive mechanisms of antiviral actions of ribavirin have been proposed. Inhibition of the inosine-monophosphatedehydrogenase enzyme after phosphorylation of ribavirin to ribavirin-5Ј-triphosphate may deplete intracellular pools of guanosine triphosphate (similar to the activity of mycophenolic acid). The second mechanism proposed is that ribavirin inhibits the guanylyltransferase by ribavirin-5Ј-triphosphate, which could interfere with the translation of cellular and viral RNA.
The approach that likely will lead to novel therapies is that directed toward unique aspects of the viral life cycle. 96 If one views the spectrum of HCV infection as a continuum from virion binding to cellular receptor on through viral replication and virion export, numerous theoretical opportunities exist that are currently being explored for development. After viral particle entry, HCV RNA targets the host cell ribosome to begin the process of viral translation. The unique mechanism by which HCV performs translation through its IRES may be a highly efficacious target for sterilization of the virus. Targeted destruction of this HCV domain may be achieved by antisense molecules 97 or ribozymes (cleaving RNA molecules). 98 After the initiation of translation of viral sequences, critical viral proteins emerge that digest the nascent polyprotein into its subunits. 71 This proteolytic function is the target of current and future protease inhibitors. Unquestionably, the emergence of protease inhibitors to the cocktail therapy of HIV has changed the horizon for patients with acquired immunodeficiency syndrome. Recent progress in the proper modeling of the HCV protease, NS3, will also lead to a rationale drug design of prospective compounds. 99 Critical to replication of the viral RNA is the need for one of the HCV proteins, NS3, to unwind (helicase activity) the comingled strands for polymerase activity and translation. 100, 101 Unfortunately, helicase inhibitors have not reached the clinic because of toxic cross-reactivity with constitutively active cellular proteins. Another target for antiviral research is the NS5b protein, which functions as the viral RNA polymerase. This editing enzyme may potentially be rendered inactive by drugs that sterically alter its structure through avid binding, compete for its viral RNA target, or poison its substrate (nucleoside analogues).
During viral assembly, some viral proteins require maturation by addition of carbohydrate or lipid molecules. These sites may prove critical for the tropism of the mature virus or its capacity to produce infection. Such maturation events are termed prenylation glycosylation and have been identified as a potential target for antiviral research. 102 
Conclusion
The identification of HCV as the etiologic agent of NANBH is certainly the most significant recent development in any area of viral disease. The clinical importance of the disease and the need to rapidly identify new therapeutic approaches has resulted in intensive study of the molecular properties of the virus. Although there are still large crevasses in our understanding of some aspects of HCV, an aggressive pursuit to bridge these gaps is underway. To develop the proper armamentarium to control HCV, a durable system of long-term viral replication must be devised, accepted, and reproduced. Such an artificial or biologically relevant system must obey important aspects of the host-viral cross-talk yet to be recorded in our patients. The rapidity with which this translational research will reach the clinic and blossom into useful therapy depends on the essential relationship that hepatologists and liver surgeons maintain and develop with those working at the bench.
The formidability of such a foe as HCV was astutely assessed by Ali Ben Abi Taleb, son-in-law of Mahomet and the fourth caliph, when he stated, ''. . . in a single enemy thou hast more than enough.'' 103
